## **REGISTERED COMPANY NUMBER: CE004367 (England and Wales) REGISTERED CHARITY NUMBER: 1163211**
## **Report of the Trustees and**
**Unaudited Financial Statements for the Year Ended 31st December 2021**
**for**
**European Parkinson's Disease Association**
A4G LLP Kings Lodge London Road West Kingsdown Sevenoaks Kent TN15 6AR
## **European Parkinson's Disease Association**
## **Contents of the Financial Statements for the Year Ended 31st December 2021**
|||**Page**||
|---|---|---|---|
|**Report of the Trustees**|1|to|8|
|**Independent Examiner's Report**||9||
|**Statement of Financial Activities**||10||
|**Statement of Financial Position**|11|to|12|
|**Statement of Cash Flows**||13||
|**Notes to the Statement of Cash Flows**||14||
|**Notes to the Financial Statements**|15|to|25|
|**Detailed Statement of Financial Activities**|26|to|28|
## **European Parkinson's Disease Association**
## **Report of the Trustees**
## **for the Year Ended 31st December 2021**
The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31st December 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).
## **Introduction**
2021 has seen once again the COVID-19 pandemic to cause continued uncertainty, impacting the EPDA and our member organisations, as well as the Parkinson's community as a whole. In spite of this, the EPDA has been able to achieve a series of remarkable results that will pave the way for **important developments** in 2022 and onwards.
In 2021, we consolidated the process to substantially improve the EPDA's **internal governance** - completing the reform of our Statutes with a focus on increased **inclusivity** . We also acquired a new member organisation and consistently increased and improved our communication with, and among, our members.
We continued to strengthen our relationships with the treatment industry, achieving a record number of **funding partners** and expanding in particular our collaboration with digital medical technology companies, and conducting win-win partnered projects benefiting the Parkinson's community directly.
After a slow-down due to the pandemic, our EU **advocacy** strategy is now being fully implemented. We have also been developing new EPDA **strategic projects** that are set to be carried out over the next three years - with an increased focus on research and the wellbeing of people with Parkinson's.
We have enlarged and deepened our relations with **Parkinson's stakeholders** in the global context - especially with the World Parkinson Congress and PD Avengers.
The EPDA also developed some impressive **online resources** (produced both independently and in partnership with the treatment industry) to provide information and support to the Parkinson's community on topics such as sleep, exercise, and nutrition.
Finally, the EPDA would not be where it is today without its members and its Board members. The EPDA Team would like to thank the EPDA Board members for contributing with their expertise, advice, and commitment to the positive results of the activities we will now describe in the following pages.
2022 is set to be an eventful year and we feel more than ready to embrace the opportunities and also the challenges as our groundwork has been set in 2021.
## **Governance**
## **Statutes:**
o Amendments were proposed and ratified by the Board and the AGM in June 2021 pertaining to membership categories
o Three membership categories were established:
-Membership (Parkinson's) organisations
o Not for profit organisations based in any European country that represent a membership of people with Parkinson's and carers.
-Affiliate
o Not for profit organisations who have a special interest in Parkinson's, with no individual members.
-Friends
o For individuals, including people with Parkinson's, carers, healthcare professionals and other people with a particular interest in Parkinson's.
Page 1
## **European Parkinson's Disease Association**
## **Report of the Trustees**
## **for the Year Ended 31st December 2021**
o These changes allow for a greater inclusivity and enable the EPDA to benefit from the wealth of expertise and experience supplied by a wider membership.
o Amends ratified at the EPDA AGM on 29 June 2021
## **Board:**
o Three new full Board members (former observers) elected by the AGM to serve for the next three years: o Gary Boyle - Ireland
o Antonella Moretti - Parkinson Italia
o Patricia Pérez Librero - Federacion Española de Parkinson
## **Results**
o A more inclusive EPDA, open to a more diverse membership o Improved expertise and representation in the Board
## **Membership**
o **One new member organisation** (MO) approved by the AGM in June 2021: Egas Moniz - Cooperativa de Ensino Superior, CRL - Portugal
o Implementation of a **members grant scheme** and the awarding of the first three winners
o Launch of a **weekly members e-shot**
o Creation of a **membership strategy** for 2022 - with a strong focus on replicating successful projects carried out by EPDA MOs across different countries
o **Virtual meetings** held with 21 EPDA MOs to discuss respective priorities, needs and areas for possible collaboration
- involving the EPDA President and Vice-President, as well as the EPDA Director General and Membership Lead o **Membership benefits:**
- Development of a simple brochure
- Design of a new website page
o Changes to **membership criteria** (see above) approved with a majority of votes by the EPDA AGM - amendment of the Affiliate Members category and introduction of the Friends category, aimed at individuals o One exclusive **communications workshop** aimed at MOs
o Dissemination of Parkinson Italia's #UnmaskParkinsons **social media campaign** :
- translation into seven languages
- eight MOs inspired by the EPDA to run the campaign in their own countries
o Two successful **members meetings** :
- in times of COVID, we believed it was essential to work more closely with our members and highlight the
- fundamental work they do for the European Parkinson's community
- the two members' meetings were held in virtual form and focused especially on:
- developing opportunities for increased collaboration and sharing of good practices between the EPDA and our members
- highlighting opportunities for our members to get involved in EPDA projects
- showcasing examples of meaningful activities carried out by our members at national levels.
## **Results**
o A more inclusive EPDA open to a more diverse membership o Improved two-way communication between EPDA and MOs
o Development of EPDA-member partnered activities on topics that are fundamental for the European Parkinson's community
## **Team improvements**
## **A new:**
o Finance Manager o Projects Support Assistant o Research Manager (starting January 2022)
Page 2
## **European Parkinson's Disease Association**
## **Report of the Trustees**
## **for the Year Ended 31st December 2021**
o Team restructuring: **streamlining roles** for all Team members
## **Results:**
o Improved expertise within the Team
o Increased our capacity to better respond to members' needs and also to engage in more projects in partnership with the treatment industry, and generally build relationships with the broader Parkinson's community o Smoother internal functioning
## **Treatment industry collaboration**
## **Funding**
o 6 Diamond partners: - AbbVie - Boston Scientific - Britannia Pharmaceuticals - Kyowa Kirin - Merz Therapeutics - Sunovion o 5 Gold partners: - Abbott - Air Liquide - BIAL - Medtronic - Servier o 5 Silver partners: - Biogen - Roche - Theravance Biopharma - UCB - Zambon
o 4 Tech partners: - Charco Neurotech
- ConvaTec
- GE Healthcare
- Orbit Health o Foundations:
- Boston Scientific Foundation Europe
## **Partnered projects include:**
o **Abbott:** development of a content campaign to raise awareness of the DBS options available to people with Parkinson's
o **AbbVie:**
- EPDA Board members supporting AbbVie in the development of its Parkinson's research investigations
- EPDA Board members supporting AbbVie in the development of patient-focused information material o **Air Liquide:** carers' survey - dissemination of results in 2021
o **Bial:**
- collaboration with Bial on the dissemination of multimedia information materials and resources from the Keep it on website and online Training Area
- continuation of the Keep ON Moving! dual-task video exercise project in collaboration with Bial
o **Britannia Pharmaceuticals:**
- development of a content campaign to raise awareness of advanced Parkinson's management and treatment options
- development of a survey on advanced Parkinson's therapies awareness and information
o **Kyowa Kirin:**
Page 3
## **European Parkinson's Disease Association**
## **Report of the Trustees**
## **for the Year Ended 31st December 2021**
- participation of the EPDA in an advisory panel on patient organisations' engagement, organised by Kyowa Kirin
- development of a multimedia content campaign on wellbeing and the impact of the Coronavirus pandemic
- development of a virtual workshop meeting on healthcare professional education
## o **Medtronic:**
- development of a webinar on DBS sensing technology
- development of a content campaign to raise awareness of advancement in DBS technology
o **Merz:** survey on sialorrhea (drooling) in Parkinson's - dissemination of results and planning of 2022 information and awareness activities on sialorrhea
o **Servier:** organisation of a workshop with people with Parkinson's, carers and advocates in collaboration with Servier
## **Results**
o Increased participation of the Parkinson's community (represented by the EPDA) in industry activities o Ultimately, the development of better treatment, support and care solutions for people with Parkinson's
## **Research**
## o **Establishment of an EPDA Research Interest Group**
- The Research Interest Group is open to all EPDA MOs and partners that are interested and passionate in becoming more active in Parkinson's research regardless of experience, skills, or knowledge.
- The group's goal is to provide a friendly forum to discuss and identify research gaps and needs and equip and enable EPDA members to engage in research and clinical trials.
## o **Successful delivery of two Patient Insight Workshops**
- In March 2021, the EPDA collaborated with one of its Gold Partners (Servier) to run two virtual 'Patient Insight Workshops'.
- The aim of the workshops was to involve people with Parkinson's in the very early stages of the clinical trial design process in order to provide research teams with new approaches and ideas.
- Discussions focused on issues such as personalised therapy, improving communication with healthcare professionals, holistic approach to treatment, digital devices for monitoring Parkinson's, and a need to improve the efficacy and safety of existing symptomatic treatment.
## **Results**
o Increased involvement of the Parkinson's community (represented by the EPDA, EPDA members and Parkinson's advocates) in the planning and design of treatment research
o Ultimately, the development of better treatment solutions for people with Parkinson's
## **Stakeholder engagement**
o **EPDA participation in WPC working groups** : Six working groups set up by World Parkinson's Coalition Partners are developing a series of themed initiatives for the World Parkinson's Congress (WPC) 2023. In 2021, various members of the EPDA Board and staff participated in four of the working groups and supported the delivery of a virtual presentation at the WPC Leadership Forum in June 2021.
o **Young-onset Parkinson's (YOPD) Working Group:** this working group is co-chaired by Russell Patten (EPDA Director General) and Gaynor Edwards, supported by Adrien Moyroud (EPDA Project Support Assistant). The group is focused on developing a global survey for YOPD called PROMISE (Patient Research On Medication, Information, Symptoms & Experience). It has also created sub-groups to focus on genetics and women.
Page 4
## **European Parkinson's Disease Association**
## **Report of the Trustees**
## **for the Year Ended 31st December 2021**
o **WPC Clinical Trials Working Group** : in 2021, Fiona Montague (EPDA Project Manager) and Dominic Graham (EPDA Operations Director) represented EPDA on the WPC Clinical Trials working group. The group has focused on identifying the barriers to accessing and taking part in research and exploring solutions with the aim of engaging more people with Parkinson's in clinical research and ensuring that each research opportunity is a good experience for all involved - regardless of the outcomes of the study. EPDA supported this work by surveying its member organisations to better understand the barriers to accessing and participating in research in different territories. The survey results were followed up by focus group discussions, which, in turn, led to the creation of the EPDA Research Interest Group (see above).
o **WPC Newly Diagnosed Working Group:** in 2021, Francesco De Renzis (EPDA Project Officer) represented the EPDA on the WPC Newly Diagnosed Working Group. The group has focused on identifying the barriers preventing people who are diagnosed with Parkinson's to engage with and seek support from Parkinson's patient organisations. The EPDA interviewed some of the EPDA members to gain a diverse, Europe-wide perspective on the topic. This resulted in identifying stigma as the main factor preventing people from seeking support; the group started exploring the possibility of developing an awareness campaign focused on stigma at a global level.
o **WPC Technology Working Group:** in 2021, EPDA President Veronica Clark represented the EPDA on the WPC Technology Working Group. The group goal is to explore existing technology that could improve life with Parkinson's and to promote innovative action, as well as to find areas of improvement that respond to unmet needs. The group is working towards developing a platform to increase access to technology services, and/or social networking that would provide better levels of care and help link people with Parkinson's, healthcare professionals and other stakeholders to technology options available.
## **Results**
o Our growing relationship with the WPC is critical given on the one hand their tremendous value and outreach to the Parkinson's community and on the other the World Parkinson Congress to be held in Europe, on our doorstep, in 2023. By actively participating in some of the leading Working Groups, we have increased our involvement with the Parkinson's community in the planning and design of treatment research, the development of better treatment solutions for people with Parkinson's and enhancing the awareness of YOPD.
## **Advocacy**
o We ran **two workshops** that addressed why and how the EPDA needs to undertake political advocacy in EU-Brussels while also supporting actions carried out by EPDA members at national level.
o With our **membership of the European Federation of Neurological Associations (EFNA)** , we have raised the profile of neurological diseases (NDs) in EU-Brussels with the support of many like-minded patient groups and the WHO. This has led to the first ever EU targeted action on NCDs - the 'Healthier Together' initiative - which will focus on neurological diseases in particular, with dedicated EU and national level support and funding streams, in 2023. o We have set up a new **Political Advocacy Working Group** (PAGs), which will work with the EPDA Team to embark on an expanded scope of activities.
o We have completed an in-depth **political stakeholder mapping** of all our key decision makers by country, which will support our MOs to work with EU decision makers in their respective countries and for the EPDA to build relationships with them in EU-Brussels.
o We have undertaken a **perception survey** , which was carried out between September 2020 and September 2021 with 50 key EU-decision makers in Brussels on their perception/understanding of Parkinson's.
o We submitted a **response to the European Commission's public consultation on the revision of the EU general pharmaceutical legislation** , due at the end of 2022. In the response, we highlighted that the new legislation should allow the EU and member states to take action to address shortages and availability, not only during times of crisis but also in the long-run to address this serious on-going issue.
## **Results**
o Raised the profile of the EPDA with policy-makers in the European institutions and with partner organisations o Increased awareness of the complexity of Parkinson's and the impact it has on people's quality of life o Ultimately, better policies and public interventions in support of people with Parkinson's, their families and carers
Page 5
## **European Parkinson's Disease Association**
## **Report of the Trustees**
## **for the Year Ended 31st December 2021**
## **Sleep and Parkinson's awareness campaign**
o **Overarching objective:** Provide and promote enhanced access and availability of sleep resources for people with Parkinson's, so they can make a more informed choice on how to improve their sleep.
## **Results**
o The campaign was a success and resonated well with people with Parkinson's. o Significant increase in engagement across all EPDA platforms as a result of the sleep content. o Feedback by a large majority was that the campaign was timely, interesting and of interest. o Involvement of several member organisations.
o Coverage and reach of key messages on electronic media
- 3,000+ web page views in May 2021
- Average reach for Facebook posts: 4,000+ in May 2021
- Total tweet reach: more than 364,000 in May 2021
- Parkinson's Life articles that resonated with readers
- Successful Touch NEUROLOGY online seminar
o A full campaign evaluation document is available here.
## **Digital communication**
o Keep ON Moving! exercise video series 2 (created in collaboration with our partner, Bial) o World Parkinson's Day 2021 video (created in collaboration with our partner, Bial) o EPDA website
- Traffic from more than 200 countries
- High engagement to the About Parkinson's and Living Well sections
o Parkinson's Life
- Parkinson's Life podcast awarded Gold Award for 'Best Branded Podcast' at the 2021 International Content Marketing
- Awards
o Social media channels
o A new Instagram page set up in May 2021
## **Parkinson's and creativity**
o In 2021, the EPDA embarked on a journey to develop **a 3D immersive arts experience** that focuses on the link between the brain, Parkinson's and creativity.
o The goal of this project is to raise awareness, inspire and encourage exploration of **Parkinson's creativity.** o The EPDA is partnering with a range of stakeholders including digital and interactive design specialists, artists, neurologists and researchers to deliver an online platform and immersive experience that all our stakeholders across Europe will have the opportuniy to participate in.
## **FINANCIAL REVIEW**
## **Going concern**
At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.
The Association's reserve policy is to hold reserves only to cover a period of 6 months administration costs. No additional reserves are intended to be held. Further analysis of restricted and unrestricted funds can be found in note 14.
Page 6
## **European Parkinson's Disease Association**
## **Report of the Trustees**
## **for the Year Ended 31st December 2021**
## **STRUCTURE, GOVERNANCE AND MANAGEMENT**
The charity was established by a charitable trust deed on 25th April 1998 in Belgium and registered as a Charitable Incorporated Organisation in the UK on 19th August 2015.
The trustees have had regard to the Charity Commission's guidance on public benefit.
## **REFERENCE AND ADMINISTRATIVE DETAILS Registered Company number**
CE004367 (England and Wales)
## **Registered Charity number**
1163211
## **Registered office**
Kings Lodge London Road West Kingsdown Sevenoaks Kent TN15 6AR
## **Trustees**
Ms M E Graham Ms V Clark Mr D J Lavender MBE Ms P Gilmore J Domingos C P Likar T Shaish Mr G Boyle (appointed 29.6.21) Ms A Moretti (appointed 29.6.21) Ms P P Librero (appointed 29.6.21)
## **Key management personnel**
Mr R Patten, Director General Mr D Graham, Operations Director Mrs L Wong, Finance Manager
## **Independent Examiner**
A4G LLP Kings Lodge London Road West Kingsdown Sevenoaks Kent TN15 6AR
Approved by order of the board of trustees on ............................................. and signed on its behalf by:
Page 7
## **European Parkinson's Disease Association**
## **Report of the Trustees for the Year Ended 31st December 2021**
................................................................. Ms V Clark - Trustee
Page 8
## **Independent Examiner's Report to the Trustees of European Parkinson's Disease Association**
## **Independent examiner's report to the trustees of European Parkinson's Disease Association ('the Company')**
I report to the charity trustees on my examination of the accounts of the Company for the year ended 31st December 2021.
## **Responsibilities and basis of report**
As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').
Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.
## **Independent examiner's statement**
Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a registered member of ICAEW which is one of the listed bodies.
I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:
1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.
Caroline Coleman ACA
A4G LLP Kings Lodge London Road West Kingsdown Sevenoaks Kent TN15 6AR
Date: .............................................
Page 9
## **European Parkinson's Disease Association**
## **Statement of Financial Activities**
## **(Incorporating an Income and Expenditure Account) for the Year Ended 31st December 2021**
|Unrestricted
funds
Notes
£
**INCOME AND ENDOWMENTS FROM**
Donations and legacies
4
31,230
**Charitable activities**
5
Other income
121,703
Bank interest
8
Project Income
21,426
Core Income
261,386
**Total**
435,752
**EXPENDITURE ON**
**Charitable activities**
6
Member organisaton and board meetings
39,480
Advocacy communication and project
development
102,035
Grant Funded projects
662
Support costs
192,541
Governance costs
2,000
Other
(84,861)
**Total**
251,857
**NET INCOME/(EXPENDITURE)**
183,895
**RECONCILIATION OF FUNDS**
**Total funds brought forward**
As previously reported
11,650
Prior year adjustment
11
(29,490)
**As restated**
(17,840)
**TOTAL FUNDS CARRIED FORWARD**
166,055|Restricted
funds
£
45,200
-
56,533
68,492
170,226
-
30,317
139,563
33,672
-
109,082
312,634
(142,408)
323,597
-
323,597
181,189|2021
Total
funds
as
£
31,230
166,903
8
77,959
329,878
605,978
39,480
132,352
140,225
226,213
2,000
24,221
564,491
41,487
335,247
(29,490)
305,757
347,244|2020
Total
funds
restated
£
28,283
-
174
-
531,508|
|---|---|---|---|
||||559,965
22,762
219,120
78,108
197,352
1,000
9,055|
||||527,397|
||||32,568
302,679
-|
||||302,679|
||||335,247|
The notes form part of these financial statements
Page 10
## **European Parkinson's Disease Association**
## **Statement of Financial Position**
## **31st December 2021**
|Notes
**CURRENT ASSETS**
Debtors
12
Cash at bank and in hand
**CREDITORS**
Amounts falling due within one year
13
**NET CURRENT ASSETS**
**TOTAL ASSETS LESS CURRENT**
**LIABILITIES**
**NET ASSETS**
**FUNDS**
15
Unrestricted funds
Restricted funds
**TOTAL FUNDS**|2021
as
£
157,862
439,558
597,420
(250,176)
347,244
347,244
347,244
166,054
181,190
347,244|2020
restated
£
133,500
457,222
590,722
(255,475)
335,247
335,247
335,247
11,650
323,597
335,247|
|---|---|---|
The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st December 2021.
The members have not required the company to obtain an audit of its financial statements for the year ended 31st December 2021 in accordance with Section 476 of the Companies Act 2006.
The trustees acknowledge their responsibilities for
- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.
The financial statements were approved by the Board of Trustees and authorised for issue on ............................................. and were signed on its behalf by:
............................................. Ms V Clark - Trustee
The notes form part of these financial statements
continued...
Page 11
## **European Parkinson's Disease Association**
## **Statement of Financial Position - continued 31st December 2021**
............................................. Mr D J Lavender MBE - Trustee
The notes form part of these financial statements
Page 12
## **European Parkinson's Disease Association**
## **Statement of Cash Flows for the Year Ended 31st December 2021**
|Notes
**Cash flows from operating activities**
Cash generated from operations
1
Net cash (used in)/provided by operating activities
**Change in cash and cash equivalents in**
**the reporting period**
**Cash and cash equivalents at the**
**beginning of the reporting period**
**Cash and cash equivalents at the end**
**of the reporting period**|2021
2020
as restated
£
£
(17,664)
45,905
(17,664)
45,905
(17,664)
45,905
457,222
411,317
439,558
457,222|
|---|---|
The notes form part of these financial statements
Page 13
## **European Parkinson's Disease Association**
## **Notes to the Statement of Cash Flows**
## **for the Year Ended 31st December 2021**
|**1.**
**RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING**
**Net income for the reporting period (as per the Statement of**
**Financial Activities)**
**Adjustments for:**
Prior year adjustments
Increase in debtors
(Decrease)/increase in creditors
**Net cash (used in)/provided by operations**|**ACTIVITIES**
2021
as
£
41,487
(29,490)
(24,362)
(5,299)
(17,664)|2020
restated
£
32,568
-
(64,796)
78,133
45,905|
|---|---|---|
## 2. **ANALYSIS OF CHANGES IN NET FUNDS**
||At 1.1.21|Cash flow|At 31.12.21|
|---|---|---|---|
||£|£|£|
|**Net cash**||||
|Cash at bank and in hand|457,222|(17,664)|439,558|
||457,222|(17,664)|439,558|
|**Total**|457,222|(17,664)|439,558|
The notes form part of these financial statements
Page 14
**European Parkinson's Disease Association**
**Notes to the Financial Statements**
## **for the Year Ended 31st December 2021**
## **1. CHARITY INFORMATION**
European Parkinson's Disease Association is a Charitable Incorporated Organisation registered in the UK on 19 August 2015.
## **2. ACCOUNTING POLICIES**
## **Accounting convention**
The accounts have been prepared in accordance with the charity's trust deed, the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016). The charity is a Public Benefit Entity as defined by FRS 102.
The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.
The financial statements are prepared in sterling , which is the functional currency of the charity. Monetary a mounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.
## **Incoming resources**
Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.
Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.
Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.
Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods and services provided in the normal course of business, net of discounts, VAT and other sales related taxes.
## **Charitable funds**
Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.
Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.
Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.
continued...
Page 15
**European Parkinson's Disease Association**
## **Notes to the Financial Statements - continued for the Year Ended 31st December 2021**
## **2. ACCOUNTING POLICIES - continued**
## **Financial instruments**
The charity has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
## **Basic financial assets**
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
## **Basic financial liabilities**
Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
## **Derecognition of financial liabilities**
Financial liabilities are derecognised when the charity’s contractual obligations expire or are discharged or cancelled.
## **Employee benefits**
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
## **Foreign exchange**
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation are included in net income/(expenditure for the period.
## **Leases**
Rentals payable under operating leases, including any lease incentives received, are charged as an expense on a straight line basis over the term of the relevant lease.
continued...
Page 16
## **European Parkinson's Disease Association**
## **Notes to the Financial Statements - continued for the Year Ended 31st December 2021**
## **2. ACCOUNTING POLICIES - continued**
## **Irrecoverable vat**
Irrecoverable VAT is charged against the expenditure heading for which it was incurred.
## **3. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY**
In the application of the charity’s accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
## **4. DONATIONS AND LEGACIES**
## **5.**
|Members fees
Donations
**INCOME FROM CHARITABLE ACTIVITIES**
Activity
Other income
Other income
Bank interest
Bank interest
Project income
Project Income
Core income
Core Income|2021
2020
as restated
£
£
25,056
23,901
6,174
4,382
31,230
28,283
2021
2020
as restated
£
£
166,903
-
8
174
77,959
-
329,878
531,508
574,748
531,682|
|---|---|
continued...
Page 17
## **European Parkinson's Disease Association**
## **Notes to the Financial Statements - continued for the Year Ended 31st December 2021**
## **6. CHARITABLE ACTIVITIES COSTS**
|**CHARITABLE ACTIVITIES COSTS**||||
|---|---|---|---|
|Member organisaton and board
meetings
Advocacy communication and project
development
Grant Funded projects
Support costs
Governance costs|Direct
Costs
£
39,480
132,352
140,225
103,368
-
415,425|Support
costs (see
note 7)
£
-
-
-
122,845
2,000
124,845|Totals
£
39,480
132,352
140,225
226,213
2,000|
||||540,270|
## **7. SUPPORT COSTS**
|**SUPPORT COSTS**||||
|---|---|---|---|
|Management
£
Support costs
4,431
Governance costs
-
4,431|Finance
£
71,365
-
71,365|Governance
Other
costs
£
£
47,049
-
1,000
1,000
48,049
1,000|Totals
£
122,845
2,000|
||||124,845|
Support costs, included in the above, are as follows:
|Advertising
Fundraising
Bad debts
Wages
Bank charges
Financial administration
Accountancy fees
Bookkeeping costs
Consultancy fees
Accountancy 2020
Bookkeeping 2020
General expenditure
Administration costs
Governance costs
Independent examination costs|Support
Governance
costs
costs
£
£
-
-
3,891
-
540
-
22,502
-
374
-
22,381
-
5,057
-
7,160
-
7,200
-
2,426
-
4,265
-
14,766
-
32,283
-
-
1,000
-
1,000
122,845
2,000|2021
2020
as restated
Total
Total
activities
activities
£
£
-
3,142
3,891
5,637
540
-
22,502
25,099
374
178
22,381
30,818
5,057
5,000
7,160
4,000
7,200
-
2,426
-
4,265
-
14,766
12,714
32,283
44,918
1,000
-
1,000
1,000
124,845
132,506|2021
2020
as restated
Total
Total
activities
activities
£
£
-
3,142
3,891
5,637
540
-
22,502
25,099
374
178
22,381
30,818
5,057
5,000
7,160
4,000
7,200
-
2,426
-
4,265
-
14,766
12,714
32,283
44,918
1,000
-
1,000
1,000
124,845
132,506|
|---|---|---|---|
||||132,506|
continued...
Page 18
**European Parkinson's Disease Association**
**Notes to the Financial Statements - continued for the Year Ended 31st December 2021**
## **8. TRUSTEES' REMUNERATION AND BENEFITS**
Ms M E Graham received fees totalling £26,008 (2020: £24,703) in connection with her role as strategic advisor. The payments have been made in accordance with the charity's constitution and approved by the other trustees.
Ms J Domingos received fees totalling £4,278 (2020: £nil) in connection with her role as project developer. The payments have been made in accordance with the charity's constitution and approved by the other trustees.
## **9. STAFF COSTS**
|Wages and salaries|2021
as
£
22,502
22,502|2020
restated
£
25,099
25,099|
|---|---|---|
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
The average monthly number of employees/trustees during the year was as follows:
|The average monthly number ofemployees/truste|esduring the year was as follows:||
|---|---|---|
||2021|2020|
|||as restated|
|Administration|2|2|
The number of employees whose employees/trustees benefits (exc luding employer pension c o sts) exceeded £60,000 was:
## **10.**
|£60,001 - £70,000
**COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**
Unrestricted
funds
£
**INCOME AND ENDOWMENTS FROM**
Donations and legacies
28,283
**Charitable activities**
Bank interest
174
Core Income
352,597
**Total**
381,054|2021
as
1
Restricted
funds
as
£
-
-
178,911
178,911|2020
restated
1
Total
funds
restated
£
28,283
174
531,508
559,965|
|---|---|---|
## **EXPENDITURE ON**
continued...
Page 19
## **European Parkinson's Disease Association**
## **Notes to the Financial Statements - continued for the Year Ended 31st December 2021**
|**10.**
**COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued**
Unrestricted
Restricted
funds
funds
as
£
£
**Charitable activities**
Member organisaton and board meetings
22,762
-
Advocacy communication and project
development
213,615
5,505
Grant Funded projects
67,809
10,299
Support costs
186,018
11,334
Governance costs
1,000
-
Other
(1,887)
10,942
**Total**
489,317
38,080
**NET INCOME/(EXPENDITURE)**
(108,263)
140,831
**RECONCILIATION OF FUNDS**
**Total funds brought forward**
119,912
182,767
**TOTAL FUNDS CARRIED FORWARD**
11,649
323,598|Total
funds
restated
£
22,762
219,120
78,108
197,352
1,000
9,055|
|---|---|
||527,397|
||32,568
302,679|
||335,247|
## **11. PRIOR YEAR ADJUSTMENT**
There is a prior year adjustments in these accounts to correct the position of trade debtors and trade creditors of previous year. This ultimately decreased the retained earnings by £29,489.52.
Due to above adjustments and requirement of presentation, all the comparatives figures would be reflected as 'as restated'.
## **12. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**
|Trade debtors
Prepayments and accrued income|2021
2020
as restated
£
£
150,017
120,397
7,845
13,103
157,862
133,500|
|---|---|
continued...
Page 20
## **European Parkinson's Disease Association**
## **Notes to the Financial Statements - continued for the Year Ended 31st December 2021**
## **13. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**
|Trade creditors
Social security and other taxes
Fund deficits
Net wages
Pension
Accruals and deferred income|2021
2020
as restated
£
£
78,336
68,718
2,059
1,878
8,075
-
7,493
7,769
514
255
153,699
176,855
250,176
255,475|
|---|---|
## **14. ANALYSIS OF NET ASSETS BETWEEN FUNDS**
|Unrestricted
funds
£
Current assets
408,155
Current liabilities
(242,101)
166,054|Restricted
funds
£
189,265
(8,075)
181,190|2021
2020
as restated
Total
Total
funds
funds
£
£
597,420
590,722
(250,176)
(255,475)
347,244
335,247|
|---|---|---|
continued...
Page 21
## **European Parkinson's Disease Association**
## **Notes to the Financial Statements - continued for the Year Ended 31st December 2021**
## **15. MOVEMENT IN FUNDS**
|**Unrestricted funds**
General fund
AbbVie (neuroscience consultation)
Parkinson's Life
**Restricted funds**
PDCS
Research/Clinical trials
Parkinson's Information
Data Collection
Treat ER
European Young Onset PD
Advanced therapies
AirLiquide Carers Project
Parkinson’s Life
Brain Life Goals
Bial
HCP Info/Educational Materials
Parkinson Sleep Project
Parkinson's Games
Tshipi's Art Exhibition
WPC Barcelona 2020
30th Anniversary
**TOTAL FUNDS**|Prior
year
At 1.1.21
adjustment
£
£
11,561
(29,490)
-
-
89
-
11,650
(29,490)
38,451
-
34,008
-
-
-
12,367
-
87,706
-
40,855
-
13,103
-
25,665
-
-
-
2,529
-
12,091
-
8,786
-
27,252
-
3,186
-
3,043
-
14,555
-
-
-
323,597
-
335,247
(29,490)|Net
movement
in funds
£
183,204
690
-
183,894
(38,451)
2,809
561
(12,367)
(8,133)
(40,855)
(13,103)
(25,665)
(5,341)
(2,529)
817
(8,786)
(27,252)
(5,920)
(3,043)
30,882
13,969
(142,407)
41,487|At
31.12.21
£
165,275
690
89
166,054
-
36,817
561
-
79,573
-
-
-
(5,341)
-
12,908
-
-
(2,734)
-
45,437
13,969
181,190
347,244|
|---|---|---|---|
continued...
Page 22
## **European Parkinson's Disease Association**
## **Notes to the Financial Statements - continued for the Year Ended 31st December 2021**
## **15. MOVEMENT IN FUNDS - continued**
Net movement in funds, included in the above are as follows:
|**Unrestricted funds**
General fund
AbbVie (neuroscience consultation)
**Restricted funds**
PDCS
Research/Clinical trials
Parkinson's Information
Data Collection
Treat ER
European Young Onset PD
Advanced therapies
AirLiquide Carers Project
Parkinson’s Life
Brain Life Goals
Bial
HCP Info/Educational Materials
Parkinson Sleep Project
Parkinson's Games
Tshipi's Art Exhibition
WPC Barcelona 2020
30th Anniversary
**TOTAL FUNDS**|Incoming
resources
£
434,499
1,252
435,751
-
-
4,302
-
-
-
-
13,593
104,573
-
9,637
-
-
4,728
7,738
25,656
-
170,227
605,978|Resources
Movement
expended
in funds
£
£
(251,295)
183,204
(562)
690
(251,857)
183,894
(38,451)
(38,451)
2,809
2,809
(3,741)
561
(12,367)
(12,367)
(8,133)
(8,133)
(40,855)
(40,855)
(13,103)
(13,103)
(39,258)
(25,665)
(109,914)
(5,341)
(2,529)
(2,529)
(8,820)
817
(8,786)
(8,786)
(27,252)
(27,252)
(10,648)
(5,920)
(10,781)
(3,043)
5,226
30,882
13,969
13,969
(312,634)
(142,407)
(564,491)
41,487|
|---|---|---|
continued...
Page 23
## **European Parkinson's Disease Association**
## **Notes to the Financial Statements - continued for the Year Ended 31st December 2021**
## **15. MOVEMENT IN FUNDS - continued**
## **Comparatives for movement in funds**
|**Unrestricted funds**
General fund
Parkinson's Life
**Restricted funds**
PDCS
Research/Clinical trials
Parkinson's Information
Data Collection
Treat ER
European Young Onset PD
Advanced therapies
AirLiquide Carers Project
Brain Life Goals
Bial
HCP Info/Educational Materials
Parkinson Sleep Project
Parkinson's Games
Tshipi's Art Exhibition
WPC Barcelona 2020
**TOTAL FUNDS**|At 1.1.20
£
124,112
(4,200)
119,912
30,637
-
7,487
12,498
91,752
40,393
-
-
-
-
-
-
-
-
-
182,767
302,679|Net
movement
in funds
£
(112,551)
4,289
(108,262)
7,814
34,008
(7,487)
(131)
(4,046)
462
13,103
25,665
2,529
12,091
8,786
27,252
3,186
3,043
14,555
140,830
32,568|At
31.12.20
£
11,561
89|
|---|---|---|---|
||||11,650
38,451
34,008
-
12,367
87,706
40,855
13,103
25,665
2,529
12,091
8,786
27,252
3,186
3,043
14,555|
||||323,597|
||||335,247|
continued...
Page 24
**European Parkinson's Disease Association**
## **Notes to the Financial Statements - continued for the Year Ended 31st December 2021**
## **15. MOVEMENT IN FUNDS - continued**
Comparative net movement in funds, included in the above are as follows:
|**Unrestricted funds**
General fund
Parkinson's Life
**Restricted funds**
PDCS
Research/Clinical trials
Parkinson's Information
Data Collection
Treat ER
European Young Onset PD
Advanced therapies
AirLiquide Carers Project
Brain Life Goals
Bial
HCP Info/Educational Materials
Parkinson Sleep Project
Parkinson's Games
Tshipi's Art Exhibition
WPC Barcelona 2020
**TOTAL FUNDS**|Incoming
resources
£
315,855
65,200
381,055
9,804
37,339
2,247
-
-
2,693
13,103
29,731
2,705
15,721
9,035
29,418
4,260
3,361
19,493
178,910
559,965|Resources
Movement
expended
in funds
£
£
(428,406)
(112,551)
(60,911)
4,289
(489,317)
(108,262)
(1,990)
7,814
(3,331)
34,008
(9,734)
(7,487)
(131)
(131)
(4,046)
(4,046)
(2,231)
462
-
13,103
(4,066)
25,665
(176)
2,529
(3,630)
12,091
(249)
8,786
(2,166)
27,252
(1,074)
3,186
(318)
3,043
(4,938)
14,555
(38,080)
140,830
(527,397)
32,568|
|---|---|---|
The term 'restricted' refers to funds that have been allocated to a specific budget heading or project by the EPDA internally and are therefore not legally required to be restricted by a particular donor. It is a the charity's discretion whether they move fund between classes as appropriate.
## **16. RELATED PARTY DISCLOSURES**
There were no related party transactions for the year ended 31st December 2021.
Page 25
## **European Parkinson's Disease Association**
|**Detailed Statement of Financial Activities**
**for the Year Ended 31st December 2021**
Unrestricted
Restricted
funds
funds
£
£
**INCOME AND ENDOWMENTS**
**Donations and legacies**
Members fees
25,056
Donations
6,174
-
-
31,229
-
**Charitable activities**
Bank interest
8
-
Other income
121,703
45,200
Core income
261,385
68,493
Project income
21,426
56,533
404,522
170,226
**Total incoming resources**
435,751
170,227
**EXPENDITURE**
**Charitable activities**
Members meeting
19,451
-
Administration Board
25,876
-
Website
13,671
420
Parkinson’s life
-
102,598
Exhibitions
490
-
Communications
18,563
-
Social media
8,625
-
Digital strategy
5,234
-
Member organisation outreach
25,009
-
GDPR
325
-
PDCS
-
3,662
Research/clinical trials
-
6,008
Parkinson's info
-
3,511
Data collection
-
-
Treat ER
-
3,425
EYOPD
-
2,931
Advocacy
53,606
-
AirLiquide carers project
569
4,448
Adviser
16,398
-
Carried forward
187,817
127,003|2021
2020
Total
Total
funds
funds
as restated
£
£
23,901
25,056
6,174
4,382
31,230
28,283
8
174
166,903
-
329,878
531,508
77,959
-
574,748
531,682
605,978
559,965
19,451
7,246
25,876
22,105
14,091
9,690
102,598
72,009
490
1,539
18,563
14,185
8,625
6,629
5,234
6,083
25,009
10,273
325
540
3,662
2,946
6,008
3,331
3,511
2,836
-
131
3,425
8,220
2,931
2,231
53,606
161,744
5,017
4,066
16,398
16,194
314,820
351,998|2021
2020
Total
Total
funds
funds
as restated
£
£
23,901
25,056
6,174
4,382
31,230
28,283
8
174
166,903
-
329,878
531,508
77,959
-
574,748
531,682
605,978
559,965
19,451
7,246
25,876
22,105
14,091
9,690
102,598
72,009
490
1,539
18,563
14,185
8,625
6,629
5,234
6,083
25,009
10,273
325
540
3,662
2,946
6,008
3,331
3,511
2,836
-
131
3,425
8,220
2,931
2,231
53,606
161,744
5,017
4,066
16,398
16,194
314,820
351,998|
|---|---|---|
|||28,283
174
-
531,508
-|
|||531,682|
|||559,965
7,246
22,105
9,690
72,009
1,539
14,185
6,629
6,083
10,273
540
2,946
3,331
2,836
131
8,220
2,231
161,744
4,066
16,194
351,998|
This page does not form part of the statutory financial statements
Page 26
## **European Parkinson's Disease Association**
## **Detailed Statement of Financial Activities**
## **for the Year Ended 31st December 2021**
|Unrestricted
Restricted
funds
funds
£
£
**Charitable activities**
Brought forward
187,817
127,003
Prevalence
1,514
-
Merz (survey/HCP awareness)
-
3,646
Medtronic Awareness projects
-
950
HCP info/education materials
-
39
Awareness campaigns
4,158
-
Brain life goals
-
1,703
Bial's
-
7,475
Servier patient insights works
2,669
-
Kyowa kirin
4,336
-
Abbott
807
-
AbbVie
533
-
Boston affiliates
102
-
Britannia (awareness)
-
5,880
CMS
2,319
-
EPDA industry meeting
2,403
-
Industry partnered projects
5,043
-
Medtronic partnered project
-
93
NeuroPath EU project
-
-
Parkinson sleep project
-
18,909
Parkinson's games
-
10,499
Sunovion research project
172
-
Tshipi's art exhibition
-
18,784
WPC Barcelona
-
8,571
211,873
203,552
**Other**
Rent
796
-
Foreign exchange losses
5,995
17,430
6,791
17,430
**Support costs**
**Management**
Advertising
-
-
Fundraising
3,891
-
Bad debts
540
-
4,431
-
**Finance**
Wages
22,502
-
Carried forward
22,502
-|2021
2020
Total
Total
funds
funds
as restated
£
£
314,820
351,998
1,514
302
3,646
3,017
950
309
39
249
4,158
2,202
1,703
176
7,475
3,630
2,669
2,838
4,336
289
807
39
533
228
102
18
5,880
507
2,319
2,208
2,403
2,048
5,043
3,177
93
147
-
612
18,909
2,166
10,499
1,074
172
3,346
18,784
318
8,571
4,938
415,425
385,836
796
1,326
23,425
7,729
24,221
9,055
-
3,142
3,891
5,637
540
-
4,431
8,779
22,502
25,099
22,502
25,099|2021
2020
Total
Total
funds
funds
as restated
£
£
314,820
351,998
1,514
302
3,646
3,017
950
309
39
249
4,158
2,202
1,703
176
7,475
3,630
2,669
2,838
4,336
289
807
39
533
228
102
18
5,880
507
2,319
2,208
2,403
2,048
5,043
3,177
93
147
-
612
18,909
2,166
10,499
1,074
172
3,346
18,784
318
8,571
4,938
415,425
385,836
796
1,326
23,425
7,729
24,221
9,055
-
3,142
3,891
5,637
540
-
4,431
8,779
22,502
25,099
22,502
25,099|
|---|---|---|
|||385,836
1,326
7,729|
|||9,055
3,142
5,637
-|
|||8,779
25,099
25,099|
This page does not form part of the statutory financial statements
Page 27
## **European Parkinson's Disease Association**
## **Detailed Statement of Financial Activities**
## **for the Year Ended 31st December 2021**
|Unrestricted
Restricted
funds
funds
£
£
**Finance**
Brought forward
22,502
-
Bank charges
374
-
Financial administration
22,381
-
Accountancy fees
5,057
-
Bookkeeping costs
7,160
-
Consultancy fees
7,200
-
Accountancy 2020
2,426
-
Bookkeeping 2020
4,265
-
71,365
-
**Other**
General expenditure
14,766
-
Administration costs
32,283
-
Governance costs
1,000
-
48,049
-
**Governance costs**
Independent examination costs
1,000
-
Total resources expended
343,509
220,982
**Net income**
92,242
(50,755)|2021
2020
Total
Total
funds
funds
as restated
£
£
22,502
25,099
374
178
22,381
30,818
5,057
5,000
7,160
4,000
7,200
-
2,426
-
4,265
-
71,365
65,095
14,766
12,714
32,283
44,918
1,000
-
48,049
57,632
1,000
1,000
564,491
527,397
41,487
32,568|2021
2020
Total
Total
funds
funds
as restated
£
£
22,502
25,099
374
178
22,381
30,818
5,057
5,000
7,160
4,000
7,200
-
2,426
-
4,265
-
71,365
65,095
14,766
12,714
32,283
44,918
1,000
-
48,049
57,632
1,000
1,000
564,491
527,397
41,487
32,568|
|---|---|---|
|||65,095
12,714
44,918
-|
|||57,632
1,000|
|||527,397|
|||32,568|
This page does not form part of the statutory financial statements
Page 28
## **European Parkinson's Disease Association**
## **Statement of Financial Activities for the Year Ended 31st December 2021**
|**INCOME AND ENDOWMENTS**
Members Fees
Donations
**Charitable Activities**
Investments
Other income
Core income
Project income
**Total incoming resources**
**EXPENDITURE**
**Charitable activities**
Members meeting
Administration Board
PDG think tank
Website
Parkinson’s life
Exhibitions
Communications
Social Media
Digital strategy
Member organisation outreach
GDPR
PDCS
Research/clinical trials
Parkinson’s info
Data collection
Treat ER
EYOPD
Advocacy
AirLiquide carers project
Adviser
Prevalence
Merz (survey/HCP awareness)
Medtronic Awareness projects
HCP info/education materials
Carried forward|25,056
6,174
31,230
8
166,903
329,878
77,959
574,748
605,978
19,451
25,876
-
14,091
102,598
490
18,563
8,625
5,234
25,009
325
3,662
6,008
3,511
-
3,425
2,931
53,606
5,017
16,398
1,514
3,646
950
39
320,969
**2021 (£)**|29,834
7,351
37,186
10
198,731
392,786
92,826
684,352
721,538
23,160
30,811
-
16,778
122,163
583
22,103
10,270
6,232
29,778
387
4,360
7,154
4,181
-
4,078
3,490
63,829
5,974
19,525
1,803
4,341
1,131
46
382,178
**2021 (€)**|23,904
4,379
28,283
174
-
531,508
-
531,682
559,965
7,246
22,105
-
9,690
72,009
1,539
14,185
6,629
6,083
10,273
540
2,946
3,331
2,836
131
8,220
2,231
161,744
4,066
16,194
302
3,017
309
249
355,875
**2020 (£)**|26,709
4,893
31,602
194
-
593,882
-
594,077
625,679
8,096
24,699
2,566
10,827
80,460
1,720
15,850
7,407
6,797
11,479
603
3,292
3,720
3,169
146
9,185
2,493
180,725
4,543
18,094
337
3,371
345
278
397,638
**2020 (€)**|
|---|---|---|---|---|
This page does not form part of the statutory financial statements Page 29
## **European Parkinson's Disease Association**
## **Statement of Financial Activities for the Year Ended 31st December 2021**
|**Charitable activities**
Brought forward
Awareness campaigns
Brain life goals
Bial's
Servier patient insights works
Kyowa kirin
Abbott
AbbVie
Boston affiliates
Britannia (awareness)
CMS
EPDA industry meeting
Industry partnered projects
Medtronic partnered project
NeuroPath EU project
Parkinson sleep project
Parkinson's games
Sunovion research project
Tshipi's art exhibition
WPC Barcelona
**Other**
Rent
**Support costs**
**Management**
Advertising
Bad debts
Fundraising
**Finance**
Wages
Bank charges
Financial administration
Accountancy fees
Bookkeeping costs
Consultancy fees
Accountancy 2020
Bookkeeping 2020
**Other**
General expenditure
Administration costs
**Governance costs**
Independent examination costs|320,969
4,158
1,703
7,475
2,669
4,336
807
533
102
5,880
2,319
2,403
5,043
93
-
18,909
10,499
172
18,784
8,571
415,425
796
-
3,891
540
4,431
22,502
374
22,381
5,057
7,160
7,200
2,426
4,265
71,365
14,766
32,283
47,049
1,000|382,178
4,951
2,028
8,900
3,178
5,163
961
635
121
7,001
2,761
2,861
6,005
111
-
22,515
12,501
205
22,366
10,205
494,647
948
-
4,633
643
5,276
26,793
445
26,649
6,021
8,525
8,573
2,889
5,078
84,974
17,582
38,439
56,021
1,191|355,875
2,202
176
3,630
2,838
289
39
228
18
507
2,208
2,048
3,177
147
612
2,166
1,074
3,346
318
4,938
385,836
1,326
3,142
-
5,637
8,779
25,099
178
30,818
5,000
4,000
-
-
-
65,095
12,714
44,918
57,632
1,000|397,638
2,460
197
4,056
3,171
323
44
255
20
566
2,467
2,288
3,550
164
684
2,420
1,200
3,739
355
5,517
431,115
1,482
3,511
-
6,299
9,809
28,044
199
34,435
5,587
4,469
-
-
-
72,734
14,206
50,189
64,395
1,117|
|---|---|---|---|---|
This page does not form part of the statutory financial statements
Page 30
## **European Parkinson's Disease Association**
## **Statement of Financial Activities for the Year Ended 31st December 2021**
|Total resources expended
**Net income before gains and losses**
**Realised recognised gains and losses**
Realised gains/(losses) on fixed asset
**Net income**|564,491
64,912
(23,425)
41,487|672,139
77,291
(27,892)
49,399|519,668
40,297
(7,729)
32,568|580,653
45,026
(8,636)
36,390|
|---|---|---|---|---|
This page does not form part of the statutory financial statements Page 31
## **European Parkinson's Disease Association**
## **Statement of Financial Activities for the Year Ended 31st December 2021**
|**CURRENT ASSETS**
Debtors
Cash at bank and in hand
**CREDITORS**
Amounts falling due within one year
**NET CURRENT ASSETS**
**TOTAL ASSETS LESS CURRENT**
**LIABILITIES**
**NET ASSETS**
**FUNDS**
Unrestricted funds
Restricted funds
**TOTAL FUNDS**|**2021 (£)**|**2021 (€)**|**2020 (£)**|149,167
510,879
660,045
(285,456)
374,589
374,589
13,017
361,572
374,589
**2020 (€)**|
|---|---|---|---|---|
||157,862
439,558
597,420
(250,176)
347,244
347,244
166,054
181,190
347,244|187,966
523,382
711,348
(297,885)
413,463
413,463
197,720
215,743
413,463|133,500
457,222
590,722
(255,475)
335,247
335,247
11,650
323,597
335,247||
This page does not form part of the statutory financial statements
Page 32